Quick-Med Technologies Announces CEO Appointment
GAINESVILLE, Florida, August 9, 2007 – Quick-Med Technologies, a life sciences company developing proprietary, advanced technologies for the healthcare and consumer markets as well as for advanced defense and homeland security medical applications, today announced that the company has appointed J. Ladd Greeno, as the company's chief executive officer, effective immediately. Concurrent with Greeno’s appointment, Quick-Med has secured new funding and commitments totaling $750,000 to fund its general operations.
Greeno is a seasoned industry executive who acquired a wealth of business and management experience during his career which includes 3 years as CEO of Agion Technologies and 25 years with consulting pioneer Arthur D. Little (ADL).
"Ladd Greeno brings a depth of business experience that will be a perfect complement to the exceptional scientific expertise of Quick-Med’s founding team," said Michael R. Granito, chairman of the board of Quick-Med. "The addition of Ladd’s experience and business acumen will accelerate our ability to better realize the powerful potential of our two technology platforms.”
Before becoming Quick-Med’s CEO, Greeno served as President and CEO of Agion Technologies, a leading provider of silver-based antimicrobials. Before joining Agion, he held a number of senior management positions at the global management and technology consulting firm, Arthur D. Little, Inc., including Chief Operating Officer and senior vice president in charge of the firm’s North American Management Consulting business. Greeno began his consulting career in ADL’s Strategy & Organization practice and then moved into leadership roles successfully building the firm’s worldwide Environmental, Health, and Safety Consulting business. His consulting experience has included dozens of assignments at the CEO or Boardroom level across multiple industries.
"It's an exciting time to be joining Quick-Med, with each of the company's two platform technologies poised for growth," said Greeno. "Drawing on my prior experience, I especially look forward to helping the Quick-Med team advance and commercialize NIMBUS®, our next generation technology that will bring a new standard to effective, bonded, and affordable antimicrobial technology.” Greeno has an MBA from the Harvard Business School. He earned his BBA degree from The University of Oklahoma.
